INTRODUCTION
TRAPS is considered to be the second most common inherited recurrent fever syndrome after a similar condition called familial Mediterranean fi ver. The disease is very rare with an estimated prevalence of approximately one per million. 1, 2 More than 1000 people have been diagnosed with TRAPS worldwide, but it is believed that there are less than 200 confi rmed cases. 3 However, true prevalence is currently unknown. (EUROTRAPS international). Mutation in TNFRSF1A gene cause TRAPS. This gene provides instructions for making a protein TNFR1. This protein is found within the membrane of cells where it binds TNF. However, some people who inherit the altered gene never develop TRAPS (reduced penetrance). TRAPS has been discovered, since the gene defect was diagnosed. TRAPS is a specifi c syndrome of dominant mode of inheritance which refers to the potency affected TNF receptor superfamily type 1A (TNFRSF1A protein).
EUROTRAPS international 1 describe 158 patient with clinical manifestation of TRAPS; of these, 53 are children and 105 adults. The annual incidence of the disease has been estimated to be 1/1,785,000 children under 16. The median age of onset is 3 years, but cases of later onset have also been described. (Fig. 2) . The mutation was previously reported as pathogenic (ClinVar Variation ID 97672). 
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First Case of TNF-Receptor-Associated Autoinfl ammatory Syndrome (TRAPS) in Bulgaria
DISCUSSION
The tumor necrosis factor receptor-associated periodic fever syndrome is recognized in the hereditary syndromes, a group of autoinfl ammatory diseases caused by inappropriate activity of the innate activity syndrome. 4 It is associated with TNFRSF1A. Most sequence variants underlying TRAPS lie within exons 2 to 4, just like it is in our case in exon 3.
Occasionally people with TRAPS develop AA amyloidosis, usually in abdominal organs and kidneys. It is estimates that 10% to 15% (or 20%) of people with TRAPS develop amyloidosis. [2] [3] [4] The disease feature in our TRAPS patient is specifi c with restrict hepatosplenomegaly AA amyloidosis without kidney damage.
Our patient has TRAPS with a history of persistent high levels of chronic infl ammation and systemic AA amyloidosis with massive hepatosplenomegaly and very minor renal involvement. Without the renal damage it would be unusual for AA type amyloidosis. SAP scan is very signifi cant in establishing the amyloid deposits.
IgA lambda light chain secreting plasma cell dyscrasia: 10 g/L. IgA lambda paraproteins on a polyclonal background, mild lambda FLC excess with lambda Bence Jones proteinuria.
Autoimmune and infectious diseases were excluded.
CONCLUSIONS
TRAPS is pleomorphic condition characterized by attacks of fever accompanied with diffuse limb pain, abdominal pain and rash in >83% of patients. 1 In many respects our patient confi rms the clinical case descriptions of early publications.
The diagnosis of TRAPS is often delayed because the signs and symptoms are not specifi c and readily recognizable. Specifi c blood tests can support a probable diagnosis. The blood tests suggesting infl ammation are high cell count, high CRP, high serum amyloid A protein and high ESR plus abnormal genetic result (mutation in the TNFRSF1A gene).
The combined EUROPEAN Union-funded projects of Eurofever and EUTRANS consist of collected data for international registry. In Bulgaria there has been no previously documented case of TRAPS.
